Follow-up
Follow-up information was obtained regularly in an outpatient clinic.
Telephone contacts to patients, physicians, and the next of kin were
performed every 6 months. The follow-up time was started after
completion of the treatment. The endpoint of the study was grade 3–4
cardiovascular adverse events (CAEs) including cardiac death,
symptomatic heart failure, arrhythmia,
Subclinical
Cardiac dysfunction with the use of established toxicity grading system
to quantify the severity of the adverse events (the Common Terminology
Criteria for Adverse Events [CTCAE] of the US National Cancer
Institute).